Premium
Treatment Adherence to Different Etanercept Regimens, Continuous vs. Intermittent, in Patients Affected by Plaque‐Type Psoriasis
Author(s) -
Esposito Maria,
Gisondi Paolo,
Cassano Nicoletta,
Babino Graziella,
Cannizzaro Maria Vittoria,
Ferrucci Giuliano,
Chimenti Sergio,
Giunta Alessandro
Publication year - 2014
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21190
Subject(s) - etanercept , medicine , regimen , psoriasis , observational study , tumor necrosis factor alpha , surgery , dermatology
Postmarketing Phase IVTreatment adherence to anti‐tumor necrosis factor alpha (anti‐ TNF ‐α) agents is marker of treatment success, but overall efficacy of anti‐ TNF ‐α therapy decreases over time leading to a progressive loss of adherence. The present observational study was conducted in order to estimate the long‐term adherence to etanercept in patients affected by plaque‐type psoriasis, evaluating differences among intermittent and continuous treatment regimen. Our findings reflect routine clinical practice in three academic referral centers and show high treatment adherence with etanercept in psoriatic patients. Treatment survival was consistently high in the short/medium term. The univariate analysis showed longer treatment duration in patients undergoing intermittent treatment regimen (mean 1,706 days) compared with continuous regimen (mean 1,249 days). Results showed that a flexible pulsed treatment with etanercept can be optimal in terms of clinical success and adherence.